
    
      This is an open label, single treatment arm clinical pilot study. The study is targeted to
      enroll twelve evaluable patients

      OBJECTIVES:

      Primary

        -  Determine the feasibility of providing extraoral LLLT for prevention of OM in pediatric
           patients undergoing HCT

      Secondary

        -  Determine the feasibility of collecting data using the WHO Oral Toxicity Scale and
           ChIMES in pediatric patients undergoing myeloablative HCT who are treated with extraoral
           LLLT for prevention of OM

        -  Evaluate the safety and tolerability of extraoral LLLT for prevention of OM in pediatric
           patients undergoing myeloablative HCT
    
  